Hyperphosphatemia Drugs Market Size
| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 3.86 Billion |
| Market Size (2030) | USD 5.31 Billion |
| CAGR (2025 - 2030) | 6.61% |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
Hyperphosphatemia Drugs Market Analysis
The Hyperphosphatemia Drugs Market size is estimated at USD 3.86 billion in 2025, and is expected to reach USD 5.31 billion by 2030, at a CAGR of 6.61% during the forecast period (2025-2030).
The increasing prevalence of chronic kidney diseases (CKD), an aging population, and strategic initiatives from industry players are expected to drive the market over the forecast period.
The market for hyperphosphatemia drugs is growing owing to the high prevalence of CKD and related risk factors. Hyperphosphatemia, a condition characterized by elevated phosphate levels in the blood, is commonly associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD). For instance, as per data from the Center for Disease Control and Prevention published in May 2024, over 37 million Americans, roughly 14% of the adult population, were affected by CKD in 2023. The condition was notably more prevalent among non-Hispanic Black adults at 20%, in contrast to 12% of non-Hispanic White adults and 14% of Hispanic adults. CKD is predominantly observed in older Americans, especially those aged 65 years and above, where the prevalence reaches 34%. Thus, as CKD rates rise globally, the demand for effective hyperphosphatemia treatments is expected to increase, contributing to market growth.
Further, risk factors such as diabetes, hypertension, and lifestyle-related conditions contribute significantly to the development of CKD, driving the need for medications that manage elevated phosphate levels. For instance, as per the Australian Institutes of Health and Welfare (AIHW), an estimated 1.3 million Australians aged 18 years and over (6.7% of the adult population) lived with one or more conditions related to heart, stroke, and vascular disease in 2022. This includes 600,000 adults (3.0%) who reported having coronary heart disease (angina and heart attack). Thus, cardiovascular diseases are associated with or exacerbate kidney problems and hyperphosphatemia. The growing prevalence of these conditions fuels the need for hyperphosphatemia management.
Further, market players are engaged in strategic activities such as product launches, clinical development, mergers, and acquisitions to gain the maximum share of the market. For instance, in December 2023, Unicycive Therapeutics Inc. enrolled its first patient in a pivotal clinical trial for Oxylanthanum Carbonate (OLC). This open-label, single-arm, multicenter, and multidose trial is a significant step for OLC, a next-generation lanthanum-based phosphate-binding agent. Leveraging proprietary nanoparticle technology, OLC is being developed for the treatment of hyperphosphatemia in dialysis patients suffering from chronic kidney disease (CKD). Such clinical development is expected to launch shortly and is likely to propel the growth of the market over the forecast period.
Therefore, the growing incidence of chronic diseases such as CKD and ESRD and related risk factors, heart and diabetes diseases, as well strategic activities by the market players, such as the introduction of new drugs and development, is anticipated to boost market growth over the projected period. However, side effects of hyperphosphatemia drugs are expected to hamper market growth.
Hyperphosphatemia Drugs Market Trends
Tablet Segment Is Expected To Hold Significant Market Share Over The Forecast Period
The growth of the tablet segment in the hyperphosphatemia drug market can be attributed to several key factors. Tablets are generally favored for their ease of administration and convenience compared to other forms like intravenous or injectable medications. They offer a more straightforward and less invasive method for patients, which can improve adherence to treatment regimens. Additionally, advancements in tablet formulation technologies have enhanced drug efficacy and patient compliance, leading to increased adoption. The cost-effectiveness of tablet production compared to other delivery forms also contributes to their growth.
As the prevalence of hyperphosphatemia rises, driven by conditions such as chronic kidney disease, the demand for tablet formulations valued for their ease of use and patient convenience is expected to increase, further propelling the market segment.
The increasing prevalence of CKD diseases across the is expected to increase demand for its tablet formulation among preferred choices due to ease of administration, thereby boosting the segment growth. For instance, as per an article published in Nephrology Dialysis Transplantation in June 2023, chronic kidney disease (CKD) affected 7.2 million people in the United Kingdom in 2023, representing over 10% of the population. The prevalence was projected to increase, with significant growth anticipated in stages 3 to 5 of CKD due to factors such as aging and rising rates of diabetes and hypertension. By 2032, the total number of individuals with CKD is expected to rise to approximately 8.61 million. Thus, the expected increase in the burden of CKD is likely to propel the segment’s growth.
In addition, according to the study published in Annals of Internal Medicine in May 2024, the efficacy of sodium-glucose co-transporter 2 (SGLT2) inhibitors in CKD management suggested that oral formulations, such as tablets, allow for better adherence and consistent dosing, which is crucial in this patient population. The study emphasized that effective management of CKD often involves combination therapies that are easier to administer in tablet form, enhancing patient compliance and overall treatment outcomes. Additionally, the convenience of tablet formulations can lead to improved patient engagement and monitoring, ultimately contributing to better management of CKD and its complications. Thus, tablet formulations are more effective in CKD patients, contributing to market growth.
Further, increasing the launch of tablet formulation and growing reimbursement is expected to increase its adoption, contributing to the segment's growth. For instance, in February 2024, Velphoro, a cutting-edge drug in the form of sucroferric oxyhydroxide chewable tablets, was added to the National Reimbursement Drug List. This next-generation, iron-based, non-calcium phosphate binder received approval in China. It is designed to manage serum phosphorus (SP) levels in adults suffering from chronic kidney disease (CKD) undergoing either hemodialysis or peritoneal dialysis. Additionally, it is effective in controlling SP levels in pediatric patients aged 12 and older, specifically those in CKD stages 4 to 5 (characterized by a glomerular filtration rate of less than 30 ml/min/1.73 m²) or those on dialysis. Thus, the introduction of tablet formulation leads to an increase in its adoption and is likely to contribute to the segment’s growth.
Thus, the growing burden of CKD and increasing launches and reimbursement for tablet formulation are expected to contribute to segment growth.
North America is Expected to Hold a Significant Market Share Over the Forecast Period
North America leads the hyperphosphatemia drugs market, driven by advanced healthcare infrastructure, high prevalence of chronic kidney disease, and significant R&D investments.
The increasing prevalence of chronic kidney disease in the region is likely to increase demand for effective drugs, contributing to market growth. As per the Centers for Disease Control and Prevention (CDC), in May 2024, 15% of adults in the United States, translating to around 37 million individuals, are estimated to have chronic kidney disease (CKD). Additionally, women exhibit a slightly higher prevalence at 14% compared to 12% in men. As CKD rates continue to rise, North America is witnessing a growing demand for effective hyperphosphatemia treatments, driven by the high number of patients affected by the disease, thereby fueling market expansion.
The major driver for this trend is the high burden of chronic disease, which leads to an increase in the use of various drugs. Age plays a crucial role in the risk of developing hyperphosphatemia, particularly affecting the geriatric population at a higher rate. For instance, as of May 2024, the Centers for Disease Control and Prevention (CDC) reported that chronic kidney disease (CKD) prevalence was notably higher in individuals aged 65 and older (33.7%) compared to those aged 45 to 64 (12.3%) and 18 to 44 (6.3%). Thus, the high prevalence of CKD in the aging population is expected to contribute to segment growth.
In the region, market players are heavily investing in the development of innovative drugs and drug approval targeting hyperphosphatemia, a move poised to bolster the market. For example, in May 2024, Strides Pharma Global received approval from the US Food and Drug Administration (FDA) for its Sevelamer Carbonate Tablets, specifically designed to combat hyperphosphatemia. Thus, the introduction of new drugs leads to an increase in its adoption and is likely to contribute to segment growth.
Thus, owing to the above factors, such as the high burden of CKD and product launches, it is expected to drive market growth over the forecast period.
Hyperphosphatemia Drugs Industry Overview
The hyperphosphatemia drug market is semi-consolidated with several players across the globe. In terms of market share, few of the major players currently dominate the market. With the increase in research and development activity, many regional players are expected to contribute to the Hyperphosphatemia drug market over the forecast period. Players are involved in mergers and acquisitions, new product development, collaborations and partnerships, and expansion strategies to augment market penetration. Some of the major players in the market are Sanofi SA, Fresenius MED Care Hldgs, Ultragenyx Pharmaceutical Inc., Ardelyx, Akebia Therapeutics Inc., Astellas Pharma Inc., Vifor Pharma Group, Takeda Pharmaceutical Company Limited, Cipla Limited, and Taro Pharmaceutical Industries Ltd.
Hyperphosphatemia Drugs Market Leaders
-
Sanofi S.A.
-
Ultragenyx Pharmaceutical Inc.
-
Fresenius MED Care Hldgs
-
Taro Pharmaceutical Industries Ltd.
-
Akebia Therapeutics Inc.
- *Disclaimer: Major Players sorted in no particular order
Hyperphosphatemia Drugs Market News
- February 2024: Ardelyx Inc. revealed that its Japanese collaboration partner, Kyowa Kirin Co. Ltd, secured approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the New Drug Application (NDA) of Tenapanor. This drug improves the condition of hyperphosphatemia in adult patients suffering from chronic kidney disease (CKD) and undergoing dialysis. In Japan, Tenapanor will be branded as PHOZEVEL.
- October 2023: The Food and Drug Administration approved Tenapanor, marketed as XPHOZAH, for treating hyperphosphatemia (high phosphorus levels) in adults with kidney disease undergoing dialysis in the United States. While phosphorus is essential for bodily functions, excessive amounts can be detrimental.
Hyperphosphatemia Drugs Industry Segmentation
As per the scope of the report, hyperphosphatemia refers to an elevated level of phosphate in the blood. Higher-than-normal levels can result from increased phosphate intake and decreased excretion of phosphate.
The hyperphosphatemia drug market is segmented by formulation, type, distribution channel, and geography. By formulation, the market is segmented as calcium-based phosphate binders, aluminum-based phosphate binders, magnesium-based phosphate binders, iron-based phosphate binders, and other phosphate binders. By type, the market is segmented into tablets, syrups, and capsules. By distribution channel, the market is segmented into hospital pharmacies and retail pharmacies. By geography, the market is segmented as North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report offers the value (USD) for the above segments.
| By Formulation | Calcium-based Phosphate Binders | ||
| Aluminum-based Phosphate Binders | |||
| Magnesium-based Phosphate Binders | |||
| Iron-based Phosphate Binders | |||
| Other Phosphate Binders | |||
| By Type | Tablets | ||
| Syrups | |||
| Capsules | |||
| By Distribution Channel | Hospital Pharmacies | ||
| Retail Pharmacies | |||
| Other Distribution Channels | |||
| By Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
Hyperphosphatemia Drugs Market Research FAQs
How big is the Hyperphosphatemia Drugs Market?
The Hyperphosphatemia Drugs Market size is expected to reach USD 3.86 billion in 2025 and grow at a CAGR of 6.61% to reach USD 5.31 billion by 2030.
What is the current Hyperphosphatemia Drugs Market size?
In 2025, the Hyperphosphatemia Drugs Market size is expected to reach USD 3.86 billion.
Who are the key players in Hyperphosphatemia Drugs Market?
Sanofi S.A., Ultragenyx Pharmaceutical Inc., Fresenius MED Care Hldgs, Taro Pharmaceutical Industries Ltd. and Akebia Therapeutics Inc. are the major companies operating in the Hyperphosphatemia Drugs Market.
Which is the fastest growing region in Hyperphosphatemia Drugs Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Hyperphosphatemia Drugs Market?
In 2025, the North America accounts for the largest market share in Hyperphosphatemia Drugs Market.
What years does this Hyperphosphatemia Drugs Market cover, and what was the market size in 2024?
In 2024, the Hyperphosphatemia Drugs Market size was estimated at USD 3.60 billion. The report covers the Hyperphosphatemia Drugs Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Hyperphosphatemia Drugs Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Hyperphosphatemia Drugs Industry Report
Statistics for the 2025 Hyperphosphatemia Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Hyperphosphatemia Drugs analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
